Cargando…

P1138: FIVE-YEAR EFFICACY AND SAFETY OF TAFASITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DLBCL: FINAL RESULTS FROM THE PHASE II L-MIND STUDY

Detalles Bibliográficos
Autores principales:	Duell, Johannes, Abrisqueta, Pau, Andre, Marc, Augustin, Marinela, Gaidano, Gianluca, González Barca, Eva, Jurczak, Wojciech, Kalakonda, Nagesh, Marina Liberati, Anna, Maddocks, Kami, Menne, Tobias, Nagy, Zsolt, Tournilhac, Olivier, Bakuli, Abhishek, Amin, Aasim, Gurbanov, Konstantin, Salles, Gilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431031/ http://dx.doi.org/10.1097/01.HS9.0000971448.45809.41

Ejemplares similares

PB2304: FIVE-YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALIDOMIDE FROM THE PHASE II L-MIND STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
por: Duell, Johannes, et al.
Publicado: (2023)

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
por: Duell, Johannes, et al.
Publicado: (2021)

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
por: Salles, Gilles, et al.
Publicado: (2021)

Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Nedved, Adrienne, et al.
Publicado: (2023)

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study
por: Belada, David, et al.
Publicado: (2023)

Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
por: Abdulhaq, Haifaa, et al.
Publicado: (2023)

The use of tafasitamab in diffuse large B-cell lymphoma
por: Düll, Johannes, et al.
Publicado: (2021)

Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
por: Nowakowski, Grzegorz S., et al.
Publicado: (2022)

Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL
por: Tabbara, Nadeem, et al.
Publicado: (2021)

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma
por: Patra-Kneuer, Maria, et al.
Publicado: (2023)

Role of MYC and BCL2 expression in a cohort of 43 patients with DLBCL: a retrospective study
por: Khan, Umair Tahir, et al.
Publicado: (2021)

Molecular Confirmation of G1138A Mutation in FGFR gene in Achondroplasia
por: Khanal, Shyam Bahadur, et al.
Publicado: (2018)

PB2102: PHASE 2 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLAMOTAMAB COMBINED WITH TAFASITAMAB (TAFA) + LENALIDOMIDE (LEN) VS TAFA+LEN IN RELAPSED OR REFRACTORY DLBCL
por: Michot, J.-M., et al.
Publicado: (2022)

1138. Retrospective Cohort Analysis of Amphotericin B Nephrotoxicity in Kidney Transplant Recipients
por: Assi, Mariam, et al.
Publicado: (2018)

1138. Script for Pediatrics: Creating a Smartphone Application to Improve Antimicrobial Prescribing
por: Primhak, Sarah, et al.
Publicado: (2019)

Preclinical study of CD19 detection methods post tafasitamab treatment
por: Ilieva, Kristina, et al.
Publicado: (2023)

Transformed Waldenström Macroglobulinemia Responsive to Tafasitamab Plus Lenalidomide: A Case Report
por: Nasir, Syed Alishan, et al.
Publicado: (2022)

PB2145: REAL-WORLD THERAPY LINES IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) – A POPULATION-BASED ANALYSIS
por: Duell, J., et al.
Publicado: (2022)

1138. Optimal Duration of Systemic Corticosteroids Use in COVID-19 Treatment: A Meta-analysis
por: Yu, Nyein, et al.
Publicado: (2022)

1138. A Scoping Review of the Role of the Provider in HPV Vaccination Dyads Research, 2012-2022
por: Clare, Alyssa F, et al.
Publicado: (2023)

The Immunology of DLBCL
por: Takahara, Taishi, et al.
Publicado: (2023)

Leptin Levels in Serum or Semen and Its Association with Male Infertility: A Meta-Analysis with 1138 Cases
por: Mo, Yi, et al.
Publicado: (2022)

Risk factors for surgical site infection in a teaching hospital: a prospective study of 1,138 patients
por: Cheng, Keping, et al.
Publicado: (2015)

1138. Utility of Methicillin-resistant Staphylococcus aureus Nares Screening in Hospitalized Children With Acute Infectious Disease Syndromes
por: Sands, Ashley, et al.
Publicado: (2021)

Check'-ing DLBCL
por: Salaverria, Itziar, et al.
Publicado: (2015)

DLBCL Coast to Coast
por: Tesio, Melania
Publicado: (2018)

GOALs in relapsed DLBCL
por: Rösler, Wiebke, et al.
Publicado: (2022)

Pityriasis lichenoides chronica in a patient on tafasitamab and lenalidomide therapy for diffuse large B-cell lymphoma
por: Roster, Katie, et al.
Publicado: (2023)

P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL
por: Zinzani, P. L., et al.
Publicado: (2022)

RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2021)

In silico characterization of a putative ORF-MAP1138c of Mycobacterium avium subspecies paratuberculosis (MAP) with its implications in virulence
por: Hassan, Syed A, et al.
Publicado: (2014)

Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy
por: Her, Jung Hyun, et al.
Publicado: (2022)

P1227: COMPREHENSIVE MOLECULAR SUBTYPING OF DIFFUSE LARGE B-CELL LYMPHOMA CELL LINES AND ASSOCIATION WITH TAFASITAMAB ACTIVITY
por: Arora, Arshi, et al.
Publicado: (2023)

Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study
por: Hawkes, Eliza A., et al.
Publicado: (2021)

DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set
por: Vrabac, Damir, et al.
Publicado: (2021)

Plasmablastic lymphoma: current perspectives
por: Lopez, Andres, et al.
Publicado: (2018)

1138. Works Well Enough? Program Directors’ Perceptions of the Effectiveness and Transparency of Competency-Based Evaluations in Assessing Infectious Diseases Fellow Performance
por: Dora, Amy V, et al.
Publicado: (2020)

PB2111: SUBGROUP ANALYSIS IN RE-MIND2, AN OBSERVATIONAL, RETROSPECTIVE COHORT STUDY OF TAFASITAMAB + LENALIDOMIDE VERSUS SYSTEMIC THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
por: Nowakowski, G. S., et al.
Publicado: (2022)

Cardiac Involvement by HIV-Associated DLBCL
por: Mupamombe, Charles T., et al.
Publicado: (2018)

The Tumor Microenvironment of DLBCL in the Computational Era
por: Opinto, Giuseppina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5lbdk8sr71r084fqmj0q1iiap1